{"denoms":[{"counts":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"124"}],"units":"Participants"}],"groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"BG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"BG001","title":"Daratumumab 16 mg/kg"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"66"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"58"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.72","value":"64.2"},{"groupId":"BG001","spread":"10","value":"62.9"},{"groupId":"BG002","spread":"9.68","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"60"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"64"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"22"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"12"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"90"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"28"}],"title":"I"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"48"}],"title":"II"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"48"}],"title":"III"}]}],"description":"The International Staging System (ISS) system consists of stage I: beta2-microglobulin less than (\\<)3.5 milligram per liter (mg/l) and albumin greater than or equal to (\\>=) 3.5 gram (g)/100 ml; stage II: neither stage I nor stage III and stage III: beta2-microglobulin \\>= 5.5 mg/l.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage of Disease (ISS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"25"}],"title":"<= 3 Lines"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"99"}],"title":"> 3 Lines"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Lines of Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"116"}],"title":"Both a PI and IMiD"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}],"title":"PI only"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"IMiD only"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"None"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Refractory to Proteasome Inhibitor (PI)/ Immunomodulatory Drug (IMiD)","unitOfMeasure":"Participants"}],"populationDescription":"All treated Analysis Set included all participants who received at least 1 dose of daratumumab."}